Alector (ALEC) Non-Current Deffered Revenue (2018 - 2026)
Alector (ALEC) posted quarterly Non-Current Deffered Revenue of $162.9 million for Q1 2026, down 4.37% year-over-year from $170.3 million in Q1 2025, and down 1.02% quarter-over-quarter from $164.5 million in Q4 2025.
Alector (ALEC) Non-Current Deffered Revenue (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Non-Current Deffered Revenue for 9 consecutive years, with $162.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 4.37% year-over-year to $162.9 million; the TTM figure through Mar 2026 stood at $162.9 million (down 4.37% YoY), while the FY2025 annual figure was $164.5 million, down 4.43% from the prior year.
- Non-Current Deffered Revenue fell to $162.9 million in Q1 2026 per ALEC's latest filing, from $164.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $505.1 million in Q1 2022 and bottomed at $162.9 million in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $262.9 million across 5 years, with a median of $204.6 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue jumped 378.83% — and 2024, when it slumped 52.54%.
- Alector's Non-Current Deffered Revenue stood at $443.4 million in 2022, then slumped by 52.44% to $210.8 million in 2023, then retreated by 18.34% to $172.2 million in 2024, then retreated by 4.43% to $164.5 million in 2025, then dropped by 1.02% to $162.9 million in 2026.
- Business Quant data shows ALEC's Non-Current Deffered Revenue at $162.9 million in Q1 2026, $164.5 million in Q4 2025, and $167.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Alector | 218.85 Mn | 46.05 Mn | - | 162.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.87 Mn |
| Mar 31, 2026 | 162.87 Mn |
| Dec 31, 2025 | 164.54 Mn |
| Sep 30, 2025 | 167.27 Mn |
| Jun 30, 2025 | 168.87 Mn |
| Mar 31, 2025 | 170.31 Mn |
| Dec 31, 2024 | 172.17 Mn |
| Sep 30, 2024 | 192.78 Mn |
| Jun 30, 2024 | 199.58 Mn |
| Mar 31, 2024 | 204.58 Mn |
| Dec 31, 2023 | 210.85 Mn |
| Sep 30, 2023 | 229.85 Mn |
| Jun 30, 2023 | 245.34 Mn |
| Mar 31, 2023 | 431.08 Mn |
| Dec 31, 2022 | 443.37 Mn |
| Sep 30, 2022 | 386.36 Mn |
| Jun 30, 2022 | 413.90 Mn |
| Mar 31, 2022 | 505.13 Mn |
| Dec 31, 2021 | 334.42 Mn |
| Sep 30, 2021 | 344.53 Mn |